Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib PK Study with Drug X, Y, and Z in Advanced Solid Tumours
NCT06929260Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceralasertib in solid tumor, sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time 0 to infinity, Area under plasma concentration-time curve from time 0 to last quantifiable concentration and 4 more. Started May 2025; status: terminated.
02
Drugs
ceralasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06929260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929260.